longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

VYLR

VYLR
----

LongbridgeAI

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

benzinga_article
Oct 2, 2026 at 12:24 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Wall Street analysts initiated coverage on five stocks with bullish outlooks. BMO Capital rated VYLR Outperform ($85), Needham rated LBRX Buy ($68), Morgan Stanley rated ELVN Overweight ($70), Keybanc rated SAIL Sector Weight, and Raymond James rated AVLN Outperform ($60). These initiations reflect positive analyst sentiment for the listed companies.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • BMO Capital analyst Joel Jackson initiated coverage on Vylor, Inc. (NYSE:VYLR) with an Outperform rating and announced a price target of $85. Vylor closed at $68.26 on Thursday. See how other analysts view this stock.
  • Needham analyst Ami Fadia initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with a Buy rating and announced a price target of $68. LB Pharmaceuticals shares closed at $37.28 on Thursday. See how other analysts view this stock.
  • Morgan Stanley analyst Sean Laaman initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN) with an Overweight rating and announced a price target of $70. Enliven Therapeutics closed at $46.21 on Thursday. See how other analysts view this stock.
  • Keybanc analyst Eric Heath initiated coverage on Sailpoint Inc (NASDAQ:SAIL) with a Sector Weight rating. SailPoint shares closed at $20.58 on Thursday. See how other analysts view this stock.
  • Raymond James analyst Tiago Fauth initiated coverage on Avalyn Pharma Inc (NASDAQ:AVLN) with an Outperform rating and announced a price target of $60. Avalyn Pharma closed at $27.42 on Thursday. See how other analysts view this stock.

Considering buying ELVN stock? Here’s what analysts think:

Photo via Shutterstock

Login to unlock927characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Avalyn Pharma

Avalyn Pharma

USAVLN

+2.59%

Enliven Therapeutics

Enliven Therapeutics

USELVN

+1.64%

LB Pharmaceuticals

LB Pharmaceuticals

USLBRX

-0.78%